MY207193A - Glyceryl 3-hydroxybutyrates for traumatic brain injury - Google Patents

Glyceryl 3-hydroxybutyrates for traumatic brain injury

Info

Publication number
MY207193A
MY207193A MYPI2019003665A MYPI2019003665A MY207193A MY 207193 A MY207193 A MY 207193A MY PI2019003665 A MYPI2019003665 A MY PI2019003665A MY PI2019003665 A MYPI2019003665 A MY PI2019003665A MY 207193 A MY207193 A MY 207193A
Authority
MY
Malaysia
Prior art keywords
brain injury
traumatic brain
glyceryl
hydroxybutyrates
oral ingestion
Prior art date
Application number
MYPI2019003665A
Other languages
English (en)
Inventor
Sami Hashim
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of MY207193A publication Critical patent/MY207193A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2019003665A 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrates for traumatic brain injury MY207193A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/404,396 US9925164B1 (en) 2017-01-12 2017-01-12 Glyceryl 3-hydroxybutyrates for traumatic brain injury
PCT/US2017/063853 WO2018132189A1 (en) 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrates for traumatic brain injury

Publications (1)

Publication Number Publication Date
MY207193A true MY207193A (en) 2025-02-05

Family

ID=61633011

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019003665A MY207193A (en) 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrates for traumatic brain injury

Country Status (11)

Country Link
US (3) US9925164B1 (enExample)
EP (1) EP3568129A4 (enExample)
JP (1) JP7278593B2 (enExample)
KR (1) KR102443942B1 (enExample)
CN (1) CN110114067A (enExample)
BR (1) BR112019014128A2 (enExample)
CA (1) CA3046355C (enExample)
IL (1) IL267934B2 (enExample)
MX (1) MX391851B (enExample)
MY (1) MY207193A (enExample)
WO (1) WO2018132189A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2020147978A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von glyceriden von hydroxycarbonsäuren
ES2965646T3 (es) * 2019-01-17 2024-04-16 Ketolipix Therapeutics Gmbh Procedimiento para la producción de lípidos que contienen unidades estructurales a base de glicéridos de ácidos hidroxicarboxílicos
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
CN113710243A (zh) * 2019-05-30 2021-11-26 神经活力投资公司 甘油三(β-羟基丁酸酯)与神经元短暂性脑缺血发作
ES2969217T3 (es) * 2019-06-12 2024-05-17 Ketolipix Therapeutics Gmbh Procedimiento para la producción de ésteres a base de poliol, en particular ésteres de poliglicerol, de ácidos hidroxicarboxílicos
CN113966323B (zh) * 2019-06-12 2023-11-28 凯托利皮克斯治疗有限责任公司 一种用于生产酮羧酸多元醇基酯的方法
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
EP4146337B1 (de) * 2020-07-13 2024-04-17 KetoLipix Therapeutics GmbH Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
AU2022387742A1 (en) 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
WO2023094654A1 (en) 2021-11-26 2023-06-01 Arxada Ag Acetoacetate based ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
US20230277484A1 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health
EP4605371A1 (en) 2022-10-18 2025-08-27 Arxada AG Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines
WO2026090272A1 (en) * 2024-10-23 2026-04-30 2508 Biosciences Llc Methods and compositions for the treatment of disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
CN103505728A (zh) 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
CA2684213A1 (en) 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
JP2009173766A (ja) 2008-01-24 2009-08-06 Ono Kogei Kk 炭素繊維含有コーティング組成物およびその調製方法
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
WO2015034812A2 (en) * 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US20190091189A1 (en) 2016-03-21 2019-03-28 Csilla Ari D'Agostino Administration of exogenous ketone to lower blood glucose
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
SG11201809211QA (en) 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US20180055797A1 (en) 2016-08-31 2018-03-01 KetoneAid Inc. Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy
JP2019526607A (ja) 2016-09-12 2019-09-19 ユニバーシティ・オブ・サウス・フロリダ ケトンにより改善された神経再生

Also Published As

Publication number Publication date
IL267934B1 (en) 2024-05-01
KR20190104546A (ko) 2019-09-10
CN110114067A (zh) 2019-08-09
JP7278593B2 (ja) 2023-05-22
JP2020504134A (ja) 2020-02-06
US9925164B1 (en) 2018-03-27
US11638702B2 (en) 2023-05-02
MX2019008269A (es) 2019-09-13
US10736867B2 (en) 2020-08-11
CA3046355C (en) 2023-08-01
IL267934B2 (en) 2024-09-01
KR102443942B1 (ko) 2022-09-15
IL267934A (en) 2019-09-26
WO2018132189A1 (en) 2018-07-19
EP3568129A4 (en) 2020-12-09
US20180193300A1 (en) 2018-07-12
CA3046355A1 (en) 2018-07-19
US20200297686A1 (en) 2020-09-24
MX391851B (es) 2025-03-21
BR112019014128A2 (pt) 2020-06-16
EP3568129A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
BR112018010024A2 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
EP4474011A3 (en) High elasticity hyaluronan compositions and methods of use thereof
WO2014190163A3 (en) Combination therapy for mds
WO2018097628A3 (ko) 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법
BR112017010953A2 (pt) composição farmacêutica
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112019024082A2 (pt) Métodos de tratamento para distonia cervical
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
EP4470625A3 (en) A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting
WO2016178510A3 (ko) 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
MX2018004489A (es) Extracto de agavaceae que comprende saponinas esteroidales y su uso para tratar y/o prevenir patologías relacionadas con desórdenes metabólicos.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
WO2020023094A3 (en) Treatment of lysosomal storage disorders
EP4335460A3 (en) Compositions and methods for treating granulomatosis with polyangiitis
WO2020036656A3 (en) Inhibition of lipofuscin aggregation by molecular tweezers
EP4480540A3 (en) A pharmaceutical composition comprising a probiotic and a prebiotic to prevent acquisition of or treat drug resistant infections
MY193625A (en) Probiotic composition for treatment or prevention of high blood cholesterol
ES2501367B1 (es) Método de tratamiento de coccidiosis
MX2017003220A (es) Metodos y formulaciones para reducir la absorcion de carbohidratos en un animal de compañia.